Available High Quality Tirze Peptides Reta Peptide Powder

You can contact me at any time~

Name:Mary

Whatsapp:+86 152 2772 7503

Email Address:sales1@xttch.com

Tirzepatide is a new type of compound peptide drug, a dual receptor agonist of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent otropic polypeptide), with strong sugar control and weight loss effects, and is an important drug in the field of metabolic diseases.

Tirzepatide is a new type of dual receptor agonist of glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent otropic polypeptide (GIP, also known as gastric inhibitory polypeptide), administered once a week. GLP-1 and GIP are both incretins, which are polypeptides secreted by the gastrointestinal mucosa of the human body. The former can bind to the receptors on the pancreatic islet cells and stimulate secretion, thereby producing a hypoglycemic effect, and can also delay gastric emptying and suppress appetite, thereby controlling weight; while the latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating release, inhibiting gastric motility and emptying, etc., which can supplement the effect of GLP-1 receptor agonists. Tirzepatide integrates two otropic effects into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

1. Drug properties
Generic name: Tirzepatide
Trade name: Tirzepatide (US), Leruiling (China, approved in 2023)
R&D company: Eli Lilly
Marketing status: First approved in the United States in 2022, approved in China in 2023 for the treatment of type 2 diabetes, currently available in many countries around the world, a prescription drug.

Appearance: white powder
Purity (HPLC) ≥95.0%
Acetate content: 5.0%~12.0%
Water content: ≤8.0%
Peptide content: ≥70.0%
Amino acid composition analysis: ≤±10%

2. Mechanism of action: Dual-target coordinated regulation of metabolism
Tirzepatide achieves multi-dimensional metabolic regulation by simultaneously activating two intestinal hormone receptors, GLP-1 and GIP:

GLP-1 receptor: promotes secretion (glucose-dependent, reduces the risk of hypoglycemia), inhibits glucagon release, delays gastric emptying, and suppresses appetite.

GIP receptor: enhances sensitivity, promotes lipolysis, improves β-cell function, and synergizes with GLP-1 receptor to amplify sugar control and weight loss effects.

Synergistic advantages: Compared with single-target GLP-1 receptor agonists (such as semaglutide), dual-target effects are stronger, especially in weight loss and improving resistance.

III. Indications
Treatment of type 2 diabetes
It is suitable for adult patients with type 2 diabetes who have poor results with metformin and other drugs on the basis of diet and exercise. It can significantly reduce the level of glycated hemoglobin (HbA1c) (average reduction of 1.5%-2.0%).

Obesity/overweight management
It is approved for weight management in adults with BMI ≥ 30kg/m² (obesity) or BMI ≥ 27kg/m² (overweight) and accompanied by at least one weight-related complication (such as hypertension, hyperlipidemia, etc.). Clinical data show that its weight loss effect is better than most single-target drugs.

IV. Dosage and Administration
Dosage form: (pre-filled pen syringe), specifications include 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg, etc.

Administration method: subcutaneous once a week, site can be selected abdomen, thigh or upper arm, no strict timing, can be administered at any time of the day (regardless of eating).

Dose adjustment: The starting dose is 2.5mg/week, gradually increased every 4 weeks according to tolerance, the maximum dose is 15mg/week (applicable to both sugar control and weight loss).

V. Clinical advantages
Strong sugar control: In multiple Phase III clinical trials (such as the SURPASS series), telpotide is better than traditional drugs such as semaglutide and glargine in reducing HbA1c, and the blood sugar standard rate is higher.

Significant weight loss: For obese/overweight people, at a dose of 15 mg per week, the average weight loss can reach 15%-20% (some patients exceed 20%), which is better than single-target GLP-1 drugs.

Metabolic improvement: It can reduce blood lipid indicators such as total cholesterol and low-density lipoprotein (LDL), improve resistance, and may have potential benefits for cardiovascular risks (relevant research is still ongoing).

Changsha Duole Technology Co., Ltd was established in 2020 with strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures.

With synthetic biology platform technology as the core, it conducts innovative research and development, mainly engaged in the research and development of recombinantly expressed pharmaceutical peptides and proteins. Its products include innovative drugs, APIs, pharmaceutical and green synthetic industrial enzymes, functional peptides and protein products, etc.

Its core team is composed of technical experts in the fields of pharmaceutical engineering, fermentation engineering and protein engineering. The company has built a 3,300-square-meter recombinant drug research and development center in Shibei, Yuelu District, Changsha City. It has a complete pharmaceutical engineering, preparation and quality research system and talent team, and has built a GMP workshop to meet the international market API supply and CDMO services.

At present, our company has realized the industrialization of a variety of biosynthetic peptide products and has obtained cooperation orders from many well-known domestic and foreign pharmaceutical companies.